OCEANIC-AF Trial Sunk; Second Renal Denervation Device Approved; Strep-Stroke Link?

(MedPage Today) -- Bayer announced that the phase III OCEANIC-AF study of the oral factor XIa inhibitor asundexian was stopped early due to inferior efficacy compared with apixaban (Eliquis) for patients with atrial fibrillation (Afib). The CDC...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news